國產醫用內窺鏡領頭羊新光維醫療遞表港交所
格隆匯4月22日丨據港交所文件,新光維醫療在港遞交上市申請,摩根士丹利、中金公司為聯席保薦人。
新光維醫療專注於醫用內窺鏡及相關創新產品的研發及商業化,其核心產品有一次性使用電子內窺鏡產品系列和重複使用內窺鏡產品。其中,一次性使用電子內窺鏡產品系列由四款已獲批准的一次性使用電子內窺鏡產品(包括3款於歐洲商業化的產品)及10款一次性使用電子內窺鏡在研產品組成。據統計,公司是國內極少數成功將高性能內窺鏡系統銷往中國三甲醫院的公司之一。
根據弗若斯特沙利文的統計,中國一次性使用醫用內窺鏡市場規模自2016年的1120萬元人民幣增至2020年的3680萬元,2016年至2020年的複合年增長率為 34.6%。預計到2025年將增至14.2億元人民幣,2020年至2025年的複合年增長率為107.6%。預計具有強大研發能力,並且可開發出性能媲美國際頂級品牌產品的國內公司將從有關增長中獲益最多。
新光維醫療主要從可重複使用內窺鏡設備(尤其是4K醫用內窺鏡攝像系統及3D圖像成像裝置)產生收入。招股書顯示,公司2020-2021年收入分別為3222.2萬元和6961.8萬元,業績實現快速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.